Smart cancer nanomedicine.,Nature Nanotechnology

当前位置： X-MOL 学术 › Nat. Nanotechnol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Smart cancer nanomedicine.
Nature Nanotechnology ( IF 38.1 ) Pub Date : 2019-11-06 , DOI: 10.1038/s41565-019-0567-y
Roy van der Meel _{1,

2,

3,

4} , Einar Sulheim _{5,

6,

7} , Yang Shi ₈ , Fabian Kiessling ₈ , Willem J M Mulder _{1,

2,

9} , Twan Lammers _{8,

10,

11}

Affiliation

Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.
Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Biotechnology and Nanomedicine, SINTEF AS, Trondheim, Norway.
Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway.
Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany.
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands.
Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands.

Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine translation and exploitation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionizing the treatment of cancer. Nanomedicines can modulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.

中文翻译：

智能癌症纳米医学。

纳米药物广泛应用于癌症治疗。我们在此提出四个战略方向来改善纳米医学转化和开发。 (1)患者分层已成为肿瘤药物开发的普遍做法。因此，癌症纳米医学迫切需要用于患者分层的探针和方案，以确定适合纳入临床试验的个体。 (2)合理的药物选择对于临床和商业成功至关重要。基于药物可用性的机会主义选择应该被模块化（前）药物和纳米载体设计的投资所取代。 (3)联合治疗是临床癌症治疗的支柱。纳米药物与药物和物理联合治疗具有协同作用，应该越来越多地整合到多模式联合治疗方案中。 (4) 免疫疗法正在彻底改变癌症的治疗方法。纳米药物可以调节骨髓细胞和淋巴细胞的行为，从而增强抗癌免疫力和免疫治疗功效。这四个方向单独，特别是一起，将推动和促进癌症纳米医学疗法的成功发展。

更新日期：2019-11-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11